Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Top-line results showed that 95% of patients treated with Dysport were revealed from severe glabellar lines with two treatments per year, and for 97% the result of the treatment seemed natural.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
December 05, 2020
Lead Product(s) : Botulinum toxin type A
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable